| Literature DB >> 31853190 |
Mansour Amin1,2, Tahereh Navidifar2,3, Farkhondeh Saleh Shooshtari2,4, Mohammad Rashno3,5, Mohammad Savari1,2, Fatemeh Jahangirmehr6, Mania Arshadi1.
Abstract
BACKGROUND: The ability of biofilm formation is an effective way for Acinetobacter baumannii survival from stressed conditions. This present study was aimed to evaluate the association between biofilm formation, structure, the expression levels of genes related to biofilm formation and biofilm-specific resistance of A. baumannii strains isolated from burn infections in Ahvaz, Iran.Entities:
Keywords: Acinetobacter baumannii; biofilm formation; biofilm structure; gene expression
Year: 2019 PMID: 31853190 PMCID: PMC6914661 DOI: 10.2147/IDR.S228981
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Primers Used in This Study
| Target | Primers | Length (bp) | Ref. |
|---|---|---|---|
| F:TAATGCTTTGATCGGCCTTG | 353 | ||
| F: GCCGACGGTCGCGATAC | 150 | ||
| F: TCAGACCGGAGAAAAACTTAACG | 150 | ||
| F: AATGCACCGGTACTTGATCC | 205 | ||
| F: ATGAAAAAGACAGCTATCGCGATTGCA | 136 | ||
| F: AATGCCTATTCCCTGCTCAC | 132 | ||
| F: ACTCCTACGGGAGGCAGCAGT | 198 |
Figure 1Dendrogram of ERIC-PCR analysis of 64 Acinetobacter baumannii strains.
MICs of Tested Antibiotics and ERIC-PCR Types for Acinetobacter baumannii Strains
| Type | Strain No. | AK | CFP | LVF | TIG | MEM | COL | Type | Strain No. | AK | CFP | LVF | TIG | MEM | COL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (µg/mL) | (µg/mL) | ||||||||||||||
| CT01 | AB11 | 64 | 128 | 8 | 16 | 64 | 1 | CT08 | AB56 | 16.0 | 4 | 4 | 0.5 | 2 | 0.5 |
| CT01 | AB01 | 64 | 128 | 8 | 16 | 64 | 0.5 | CT09 | AB38 | 128 | 512 | 128 | 8 | 8 | 0.25 |
| CT01 | AB02 | 128 | 128 | 8 | 16 | 128 | 0.25 | CT09 | AB35 | 128 | 256 | 128 | 4 | 8 | 0.25 |
| CT02 | AB19 | 128 | 64 | 1 | 2 | 1 | 1 | CT09 | AB36 | 64 | 256 | 128 | 8 | 8 | 1 |
| CT02 | AB20 | 128 | 128 | 1 | 2 | 1 | 1 | CT10 | AB37 | 128 | 8 | 8 | 2 | 256 | 1 |
| CT02 | AB62 | 128 | 64 | 2 | 2 | 1 | 0.5 | CT10 | AB34 | 128 | 16 | 8 | 1 | 256 | 0.25 |
| CT03 | AB03 | 256 | 512 | 16 | 8 | 256 | 1 | CT10 | AB39 | 128 | 16 | 8 | 4 | 128 | 0.25 |
| CT03 | AB04 | 256 | 512 | 16 | 8 | 512 | 0.5 | CT10 | AB40 | 64 | 8 | 4 | 1 | 128 | 1 |
| CT03 | AB42 | 256 | 256 | 16 | 4 | 512 | 0.5 | CT10 | AB10 | 64 | 16 | 4 | 4 | 128 | 1 |
| CT03 | AB41 | 256 | 512 | 32 | 4 | 512 | 0.25 | CT10 | AB09 | 128 | 16 | 4 | 2 | 256 | 0.5 |
| CT03 | AB08 | 256 | 512 | 16 | 8 | 256 | 0.25 | CT11 | AB43 | 128 | 128 | 64 | 16 | 512 | 0.5 |
| ST01 | AB15 | 16 | 16 | 32 | 4 | 512 | 1 | CT11 | AB44 | 128 | 128 | 64 | 4 | 512 | 0.5 |
| CT04 | AB64 | 16 | 4 | 2 | 0.5 | 2 | 0.5 | CT11 | AB45 | 256 | 128 | 64 | 8 | 1024 | 0.25 |
| CT04 | AB12 | 16 | 4 | 2 | 0.5 | 2 | 0.5 | CT11 | AB47 | 256 | 128 | 32 | 4 | 256 | 0.25 |
| ST02 | AB16 | 512 | 512 | 4 | 4 | 64 | 0.5 | CT11 | AB46 | 512 | 128 | 32 | 4 | 512 | 1 |
| ST03 | AB18 | 512 | 256 | 4 | 4 | 256 | 1 | CT11 | AB32 | 512 | 128 | 64 | 16 | 512 | 1 |
| CT05 | AB17 | 512 | 512 | 64 | 16 | 512 | 0.5 | CT11 | AB49 | 256 | 256 | 64 | 16 | 512 | 1 |
| CT05 | AB05 | 256 | 512 | 64 | 32 | 256 | 1 | CT11 | AB31 | 512 | 128 | 32 | 16 | 1024 | 0.25 |
| CT05 | AB06 | 512 | 256 | 64 | 16 | 256 | 0.5 | ST07 | AB51 | 64 | 512 | 64 | 0.5 | 64 | 0.25 |
| ST04 | AB07 | 64 | 512 | 128 | 4 | 512 | 0.25 | ST08 | AB52 | 16 | 2 | 512 | 1 | 64 | 0.5 |
| CT06 | AB21 | 8 | 4 | 1 | 4 | 4 | 0.25 | CT12 | AB54 | 512 | 1 | 4 | 4 | 64 | 0.5 |
| CT06 | AB22 | 8 | 4 | 1 | 4 | 4 | 0.5 | CT12 | AB53 | 512 | 0.5 | 4 | 4 | 128 | 0.25 |
| ST05 | AB28 | 256 | 16 | 4 | 1 | 512 | 0.5 | CT13 | AB50 | 64 | 1 | 128 | 1 | 2 | 0.25 |
| CT07 | AB24 | 512 | 128 | 64 | 4 | 256 | 0.25 | CT13 | AB33 | 64 | 2 | 128 | 0.5 | 2 | 0.25 |
| CT07 | AB25 | 512 | 128 | 64 | 4 | 128 | 0.25 | ST09 | AB57 | 16 | 1 | 64 | 0.5 | 1 | 0.5 |
| CT07 | AB26 | 512 | 256 | 128 | 4 | 128 | 1 | ST10 | AB58 | 256 | 16 | 4 | 0.5 | 256 | 1 |
| ST06 | AB23 | 256 | 16 | 4 | 4 | 128 | 0.25 | ST11 | AB59 | 512 | 8. | 4 | 0.5 | 512 | 1 |
| CT08 | AB27 | 16 | 8 | 2 | 0.5 | 2 | 0.5 | CT14 | AB60 | 128 | 512 | 64 | 2 | 64 | 0.5 |
| CT08 | AB29 | 16 | 4 | 2 | 0.25 | 2 | 0.25 | CT14 | AB61 | 256 | 512 | 128 | 2 | 128 | 0.5 |
| CT08 | AB30 | 16 | 8 | 4 | 4 | 1 | 0.5 | CT14 | AB13 | 128 | 256 | 128 | 2 | 128 | 0.5 |
| CT08 | AB55 | 32 | 8 | 4 | 4 | 2 | 1 | CT14 | AB63 | 128 | 256 | 128 | 2 | 128 | 0.5 |
| CT08 | AB48 | 32 | 4 | 2 | 0.5 | 1 | 0.25 | CT14 | AB14 | 256 | 256 | 64 | 1 | 128 | 0.25 |
Abbreviations: CT, clonal type; ST, single type; AK, amikacin; LVF, levofloxacin; CEF, cefepime; TIG, tigecycline; COL, colistin; MEM, meropenem.
Biofilm-Forming Capacity (OD570), Composition of the biofilm Matrix and ERIC-PCR Type of Acinetobacter baumannii Strains
| Type | Strain | Capacity of Biofilm Formation | Removed Biofilm | Type | Strain | Capacity of Biofilm Formation | Removed Biofilm | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NaIO4 | PK | DNAseI | NaIO4 | PK | DNAseI | ||||||
| CT01 | AB11 | Weak | ++ | + | + | CT08 | AB56 | Strong | +++ | + | − |
| CT01 | AB01 | Weak | ++ | + | + | CT09 | AB38 | Weak | ++ | − | ++ |
| CT01 | AB02 | Weak | ++ | + | + | CT09 | AB35 | Weak | ++ | − | ++ |
| CT02 | AB19 | Strong | +++ | + | – | CT09 | AB36 | Weak | ++ | − | ++ |
| CT02 | AB20 | Strong | +++ | + | – | CT10 | AB37 | Intermediate | +++ | + | − |
| CT02 | AB62 | Strong | +++ | + | – | CT10 | AB34 | Intermediate | +++ | + | − |
| CT03 | AB03 | Weak | +++ | – | – | CT10 | AB39 | Intermediate | +++ | + | − |
| CT03 | AB04 | Weak | +++ | – | – | CT10 | AB40 | Intermediate | +++ | + | − |
| CT03 | AB42 | Weak | +++ | – | – | CT10 | AB10 | Intermediate | +++ | + | − |
| CT03 | AB41 | Weak | +++ | – | – | CT10 | AB09 | Intermediate | +++ | + | − |
| CT03 | AB08 | Weak | +++ | – | – | CT11 | AB43 | Weak | ++ | + | + |
| ST01 | AB15 | None | – | – | – | CT11 | AB44 | Weak | ++ | + | + |
| CT04 | AB64 | Strong | ++ | + | + | CT11 | AB45 | Weak | ++ | + | + |
| CT04 | AB12 | Strong | ++ | + | + | CT11 | AB47 | Weak | ++ | + | + |
| ST02 | AB16 | None | – | – | – | CT11 | AB46 | Weak | ++ | + | + |
| ST03 | AB18 | None | – | – | – | CT11 | AB32 | Weak | ++ | + | + |
| CT05 | AB17 | Weak | +++ | + | – | CT11 | AB49 | Weak | ++ | + | + |
| CT05 | AB05 | Weak | +++ | + | – | CT11 | AB31 | Weak | ++ | + | + |
| CT05 | AB06 | Weak | +++ | + | – | ST07 | AB51 | Weak | +++ | – | + |
| ST04 | AB07 | Weak | +++ | – | + | ST08 | AB52 | Strong | ++ | + | + |
| CT06 | AB21 | Strong | ++ | ++ | – | CT12 | AB54 | None | – | – | – |
| CT06 | AB22 | Strong | ++ | ++ | – | CT12 | AB53 | None | – | – | – |
| ST05 | AB28 | None | – | – | – | CT13 | AB50 | Intermediate | ++ | ++ | – |
| CT07 | AB24 | Weak | ++ | ++ | – | CT13 | AB33 | Intermediate | ++ | ++ | – |
| CT07 | AB25 | Weak | ++ | ++ | – | ST09 | AB57 | Strong | + | ++ | + |
| CT07 | AB26 | Weak | ++ | ++ | – | ST10 | AB58 | None | – | – | – |
| ST06 | AB23 | None | – | – | – | ST11 | AB59 | None | – | – | – |
| CT08 | AB27 | Strong | +++ | + | – | CT14 | AB60 | Intermediate | +++ | – | + |
| CT08 | AB29 | Strong | +++ | + | – | CT14 | AB61 | Intermediate | +++ | – | + |
| CT08 | AB30 | Strong | +++ | + | – | CT14 | AB13 | Intermediate | +++ | – | + |
| CT08 | AB55 | Strong | +++ | + | – | CT14 | AB63 | Intermediate | +++ | – | + |
| CT08 | AB48 | Strong | +++ | + | – | CT14 | AB14 | Intermediate | +++ | – | + |
Abbreviations: CT, clonal type; ST, single type; NaIO4, sodium metaperiodate; PK, proteinase K; + = ≤30%; ++ = 30–70% and +++ = ≥70%.
Association Between the Biofilm-Forming Capacities and Antibiotic Resistance
| Antibiotic Agents | Optical Density 570 | rs | P value | ||
|---|---|---|---|---|---|
| Susceptible Moderate Resistance | |||||
| Amikacin | 0.950(0.917–0.984) | 0.687(0.051–0.974) | 0.206(0.047–0.864) | −0.708 | <0.001 |
| Meropenem | 0.748(0.741–0.755) | 0.728 (0.051–0.984) | 0.181(0.047–0.302) | −0.664 | <0.001 |
| Levofloxacin | 0.809(0.630–0.954) | 0.298(0.047–0.984) | 0.192(0.051–0.874) | −0.258 | <0.001 |
| Tigecycline | 0.458(0.047–0.954) | 0.265(0.054–0.284) | 0.141(0.114–0.164) | −0.479 | <0.001 |
| Cefepime | 0.563(0.051–0.984) | 0.219(0.054–0.864) | 0.166 (0.047–0.287) | −0.406 | 0.001 |
| Colistin | 0.312(0.047–0.984) | – | – | −0.030 | 0.813 |
Association Between the Biofilm Formation Capacity, the Clonal Types and Gene Profiles
| Capacity of Biofilm Formation | Gene Profile | ERIC-PCR Type | Frequency (%) |
|---|---|---|---|
| Strong | CT02, CT04, CT06 CT08,ST08, ST09 | 15 (23.43) | |
| Moderate | CT14,CT10 | 3 (4.6) | |
| CT14 | 2 (3.1) | ||
| CT13, CT14, CT10 | 8 (12.5) | ||
| Weak | CT01, CT03, CT11,ST04, ST07 | 18 (28.12) | |
| CT05 | 3 (4.6) | ||
| CT07, CT09 | 6 (9.37) | ||
| None | ST01,ST02, ST05,ST10 | 4 (6.25) | |
| CT12,ST11, ST06,ST03 | 5 (7.8) |
Association Between the Expression Levels of Genes Involved in Biofilm Formation and the biofilm formation Capacity
| Capacity of Biofilm Formation | |||||
|---|---|---|---|---|---|
| Weak | 0.65(0.54–0.75) | 0.60(0.41–0.95) | 0.71(0.54–0.91) | 0.71 (0.62–0.85) | 2.58(1.65–3.65) |
| Intermediate | 1.91(1.43–2.41) | 1.02(0.84–1.56) | 1.18(0.82–1.95) | 1.29(0.84–1.64) | 0.72(0.54–0.95) |
| Strong | 4.73 (2.65–6.31) | 3.87(2.11–5.32) | 3.87(2.65–4.62) | 4.03(2.23–7.14) | 4.41(2.92–7.45) |
| No biofilm | 0 | 0.59(0.41–0.84) | 0 | 0.50(0.45–0.63) | 1.97(1.52–2.23) |
| <0.01 | <0.01 | <0.01 | <0.01 | <0.01 |
Expression Levels of mRNA of the adeB, adeJ and adeG Genes with Regard to Non-Susceptible to Antibiotics
| Antibiotic | Group | MIC (µg/mL) | Gene Expression of | ||
|---|---|---|---|---|---|
| Cefepime | Susceptible (n=19) | ≤8 | <1; n=3 | <1; n=8 | <1; n=9 |
| 1.31–9.47; n=10 | 1.37–1.85; n=11 | 1.39–4.65; n=3 | |||
| 10.22–85.63; n=6 | 10.1–69.35; n=5 | ||||
| Non-susceptible (n=45) | 16–128 | <1; n=3 | <1; n=11 | <1; n=9 | |
| 1.16–6.41; n=15 | 1.23–1.96; n=12 | 1.23–8.65; n=10 | |||
| 15.97–52.15; n=5 | 12.32–41.32; n=4 | ||||
| ≥256 | <1; n=5 | <1; n=10 | <1; n=6 | ||
| 1.14–8.47; n=17 | 1.23–1.89; n=12 | 1.56–8.45; n=9 | |||
| 12.36–75.21; n=7 | |||||
| Amikacin | Susceptible (n=11) | ≤16 | <1; n=1 | <1; n=3 | <1; n=6 |
| 1.45–9.74; n=5 | 1.37–1.85; n=8 | 2.35–4.45; n=2 | |||
| 10.22–85.63; n=5 | 12.5–69.35; n=3 | ||||
| Non-susceptible (n=53) | 32–128 | <1; n=5 | <1; n=11 | <1; n=8 | |
| 1.16–6.41; n=16 | 1.23–1.89; n=13 | 1.32–8.65; n=13 | |||
| 18.64–52.15; n=3 | 12.59–41.32;n=3 | ||||
| ≥256 | <1; n=5 | <1; n=15 | <1; n=12 | ||
| 1.14–8.47; n=22 | 1.23–1.95; n=14 | 1.23–3.76; n=7 | |||
| 15.97–30.41; n=2 | 10.1–75.21;n=10 | ||||
| Tigecycline | Susceptible (n=26) | ≤2 | <1; n=5 | <1; n=7 | <1; n=12 |
| 1.14–9.47; n=16 | 1.23–1.89; n=19 | 1.32–8.65; n=10 | |||
| 19.84–85.63; n=5 | 12.25–69.34; n=4 | ||||
| Non-susceptible (n=38) | 4–32 | <1; n=6 | <1; n=22 | <1; n=14 | |
| 1.14–8.74; n=26 | 1.23–1.96; n=16 | 1.23–8.45; n=12 | |||
| 10.22–37.14; n=6 | 10.1–75.21; n=12 | ||||
| Meropenem | Susceptible (n=14) | ≤2 | <1; n=3 | <1; n=5 | <1; n=8 |
| 1.14–9.47; n=6 | 1.23–1.69; n=9 | 1.39–8.69; n=3 | |||
| 34.14–85.63; n=5 | 12.25–69.35; n=3 | ||||
| Non-susceptible (n=50) | 4–64 | <1; n=2 | <1; n=7 | <1; n=3 | |
| 1.45–6.41; n=8 | 1.5–1.86; n=5 | 1.56–4.65; n=7 | |||
| 10.22–19.84; n=2 | 10.1–12.95; n=2 | ||||
| 128–1024 | <1; n=6 | <1; n=17 | <1; n=15 | ||
| 1.14–8.74; n=28 | 1.23–1.96; n=23 | 1.23–8.45; n=12 | |||
| 15.97–37.14; n=4 | 10.65–75.21; n=11 | ||||
| Levofloxacin | Susceptible (n=10) | ≤2 | <1; n=1 | <1; n=3 | <1; n=3 |
| 1.16–9.47; n=4 | 1.23–1.52; n=7 | 2.36–8.65; n=4 | |||
| 10.22–85.63; n=5 | 12.25–69.35; n=3 | ||||
| Non-susceptible (n=54) | 4–32 | <1; n=2 | <1; n=18 | <1; n=14 | |
| 1.16–6.41; n=22 | 1.23–1.96; n=11 | 1.23–4.56; n=6 | |||
| 15.97–37.14; n=5 | 10.1–75.21; n=9 | ||||
| 64–512 | <1; n=8 | <1; n=8 | <1; n=9 | ||
| 1.14–8.47; n=14 | 1.25–1.89; n=17 | 1.23–8.45; n=12 | |||
| 19.84; n=1 | 12.25–51.23; n=4 | ||||
Expression Levels of mRNA of the adeB, adeJ and adeG Genes with Regard to Capacity of Biofilm Formation
| Capacity of Biofilm Formation (Number) | Gene Expression Level | |||||
|---|---|---|---|---|---|---|
| (Number) | (Number) | (Number) | ||||
| Non-biofilm (n=9) | 1<; | n=1 | 1<; | n=4 | 1<; | n=5 |
| 1.32–6.34; | n=7 | 1.65–1.96; | n=5 | 2.58–15.63; | n=4 | |
| 37.34; | n=1 | |||||
| Weak (n=27) | 1<; | n=5 | 1<; | n=16 | 1<; | n=8 |
| 1.32–6.34; | n=20 | 1.32–1.85; | n=11 | 1.32–8.45; | n=10 | |
| 37.34; | n=2 | 12.36–75.21; | n=9 | |||
| Intermediate (n=13) | 1<; | n=3 | 1<; | n=3 | 1<; | n=5 |
| 1.14–2.64; | n=9 | 1.39–1.89; | n=10 | 1.32–3.78; | n=7 | |
| 18.64; | n=1 | 15.69; | n=1 | |||
| Strong (n=15) | 1<; | n=2 | 1<; | n=6 | 1<; | n=8 |
| 1.16–9.47; | n=6 | 1.23–1.58; | n=9 | 2.36–8.45; | n=4 | |
| 10.22–85.63; | n=7 | 12.25–69.35; | n=3 | |||
| P value | 0.298 | 0.004 | 0.899 | |||